ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine

THOUSAND OAKS, Calif., Feb. 11, 2011 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries. (www.biocentury.com)

The publication noted that, ImmunGene's CEO Sanjay Khare "anticipates licensing deals will be a key part of ImmunGene's strategy. 'We see a potential model where we out-license our cytokine payload technology and in-license antibodies or antibody targets that will deliver the payload to treat cancer and perhaps other diseases,' he said."

Dr. Sanjay Khare also said, "We are pleased to receive recognition from a global biotech publication for ImmunGene's interferon payload technology and pipeline of next generation of armed antibodies for cancer. Our platform technology, available for non-exclusive licensing, offers the possibility of lower doses of drug for clinical efficacy which will result in the lower cost of goods along with patient convenience and may reduce hospitalization cost."

"We are in advanced discussions with several biotech/pharma companies for both product and technology partnerships," Dr. Khare added.

About BioCentury

BioCentury Publications, Inc. is internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.

About ImmunGene, Inc.

ImmunGene is a privately-held, drug discovery and development company, tapping the power of the immune system to develop the next generation of antibody-based therapeutics to treat cancer, autoimmune and infectious diseases. Our technology platform, available for non-exclusive licensing, offers pharma and biotech companies the possibility of utilizing lower doses of their drug candidates for enhanced clinical efficacy, simplifying the manufacturing process, and lowering cost of goods. Our three novel pipeline candidates are antibody-cytokine fusions that have demonstrated targeted efficacy superior to existing therapies in vitro and in vivo testing. For more information please visit www.immungene.com.

This press release contains certain forward-looking statements relating to our business. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs. There can be no assurance that any product in ImmunGene's pipeline or technology platform will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

SOURCE ImmunGene, Inc.